Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine/Naloxone for HIV Prevention in Opiate Injectors
NCT00270257Phase 3Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2008
- Primary completion
- Jul 2012
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of buprenorphine and naloxone in human immunodeficiency virus infection (HIV) and opioid use disorder (OUD) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Evidence of HIV-1 Infection or Death at 104 weeks. Started May 2008; status: terminated.
02
Drugs
buprenorphinenaloxone
03
Conditions
human immunodeficiency virus infection (HIV)opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT00270257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00270257.